JEANNE Y. WEI, M.D.; BERNADINE H. BULKLEY, M.D.; ALLEN H. SCHAEFFER, M.D.; H. LEON GREENE, M.D.; PHILIP R. REID, M.D.
▸Requests for reprints should be addressed to Philip R. Reid, M.D.; Osler 503, The Johns Hopkins Hospital; Baltimore, MD 21205.
WEI JY, BULKLEY BH, SCHAEFFER AH, GREENE HL, REID PR. Mitral-Valve Prolapse Syndrome and Recurrent Ventricular Tachyarrhythmias: A Malignant Variant Refractory to Conventional Drug Therapy. Ann Intern Med. 1978;89:6-9. doi: 10.7326/0003-4819-89-1-6
Download citation file:
Published: Ann Intern Med. 1978;89(1):6-9.
Of 60 patients referred for management of drug-refractory ventricular tachyarrhythmias, 10 (17%) had mitral-valve prolapse. These 10 patients ranged in age from 19 to 70 years (mean, 47 years); seven were women. All 10 had recurrent ventricular tachycardia, while four had a history of ventricular fibrillation. Nine patients were refractory to propranolol in combination with one or more of the standard antiarrhythmic agents. All showed improvement with aprindine therapy. The results show that refractory malignant ventricular arrhythmias may be associated with the mitral-valve prolapse syndrome; patients with mitral-valve prolapse account for a rather high percentage of those patients referred with recurrent drug-refractory ventricular tachyarrhythmias; in patients with unexplained ventricular arrhythmias, mitral-valve prolapse should be considered; and aprindine may be effective for ventricular tachyarrhythmias associated with mitral-valve prolapse.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Rhythm Disorders and Devices, Valvular Heart Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only